Stock Price & Analysis

The price target for JANX stock in 2025 is predicted to be around $35, driven by its oversold condition and potential upside from promising clinical trial results. The stock currently trades at $30.83, with a Fibonacci pivot point at $30.90, suggesting near-term support. Analysts have mixed opinions, with some lowering targets but others maintaining a strong buy rating.

The S1 support level for JANX Stock is $29.3 ,The R1 resistant level for JANX Stock is $31.66.

As of the end of day on 2025-03-28, the price of JANX Stock was $29.15.

The target price for JANX Stock according to analyst rating is 98.44, with the highest price target at 200.00 and the lowest at 41.00. Analysts have a Strong Buy rating on JANX Stock overall.

The market cap of JANX is $1.7B.

Analysis and Insights

Valuation Metrics:

JANX's current stock price is $30.83, with a price-to-sales (PS) ratio of 236.78, indicating a premium valuation compared to industry peers. The lack of earnings per share (EPS) and negative EBITDA makes it challenging to justify the current price based on fundamentals.

Recent News and Analyst Sentiment:

Scotiabank lowered JANX's price target from $62 to $41, citing unmet benchmarks in the Phase 1 trial of JANX007. Despite this, other analysts maintain a "Strong Buy" rating, highlighting the potential of JANX's pipeline.

Insider and Institutional Activity:

The Chief Business Officer sold 901 shares, while 146 institutional investors increased their positions, reflecting mixed sentiment. This contrasts with 82 institutions reducing their holdings.

Stock Performance:

JANX's stock has declined from $41 to $30.83, with a 2.87% drop today. The high PS ratio and lack of profitability suggest overvaluation.

Conclusion:

JANX appears overvalued due to its high stock price without earnings, Scotiabank's price target reduction, and insider selling. While some analysts remain optimistic, the lack of profitability and high valuation metrics raise concerns.

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidate includes JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr), being investigated in a Phase I clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Price Prediction for JANX Stock by 2030

Based on current trends and analysis, JANX stock is predicted to reach $76 by 2030, driven by promising clinical trial results and strategic growth plans. The stock may face challenges due to mixed analyst sentiment and insider selling activity. A more conservative estimate suggests a potential stabilization around $41 if trial benchmarks are not fully met.

JANX has a total of 64 employees.